<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )</h1>

    <table>
      <tr><th>Ticker</th><td>KPTI</td></tr>
      <tr><th>Float</th><td>16.9 M</td></tr>
      <tr><th>IO</th><td>36.28%</td></tr>
      <tr><th>MC</th><td>125 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Adage Capital Management, L.P., Robert Atchinson and Phillip Gross filed a Schedule 13G (Amendment No. 1) reporting beneficial ownership of 436,736 shares of Karyopharm Therapeutics Inc. common stock (CUSIP 48576U205), representing 2.38% of the outstanding shares (based on 18,310,283 shares outstanding as of 12/29/2025). The reported amount includes 15,414 shares issuable upon exercise of warrants held by Adage Capital Partners, L.P. The filing certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control (passive intent). Filing signed 02/12/2026.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Reporting persons: Adage Capital Management, L.P.; Robert Atchinson; Phillip Gross.</li><li>Beneficial ownership reported: 436,736 shares (includes 15,414 shares issuable upon exercise of warrants).</li><li>Stake equals 2.38% of outstanding common stock (based on 18,310,283 shares outstanding as of 12/29/2025).</li><li>Filing certifies holdings are passive and held in the ordinary course of business.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Reported stake is below 5% (2.38%), limiting influence and avoiding Schedule 13D thresholds.</li><li>No indication of intent to influence or change control of the issuer.</li></ul>
    </div>

    <div class="section">
      <a href="https://www.sec.gov/Archives/edgar/data/1503802/000090266426000896/0000902664-26-000896-index.htm" target="_blank">Original Article</a>
    </div>

    <div class="small">KPTI â€¢ TradersLink AI News</div>
  </div>
</body>
</html>